Corvus Pharmaceuticals Inc Stock
Corvus Pharmaceuticals Inc gained 0.360% compared to yesterday.
We see a rather positive sentiment for Corvus Pharmaceuticals Inc with 7 Buy predictions and 1 Sell predictions.
With a target price of 27 € there is potential for a 142.04% increase which would mean more than doubling the current price of 11.16 € for Corvus Pharmaceuticals Inc.
Our community identified positive and negative aspects for Corvus Pharmaceuticals Inc stock for the coming years. 6 users see the criterium "Worthwhile Investment for the next years" as a plus for the Corvus Pharmaceuticals Inc stock. On the other hand our users think that "General Risks" could be a problem in the future.
Pros and Cons of Corvus Pharmaceuticals Inc in the next few years
Pros
?
M***** P*******
?
B****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Corvus Pharmaceuticals Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Corvus Pharmaceuticals Inc | 0.360% | -4.387% | -12.169% | 215.319% | 79.564% | 461.364% | 524.438% |
| Evolus Inc | -1.260% | -3.871% | -15.000% | -34.208% | -7.046% | -44.330% | -42.757% |
| Heron Therapeutics Inc. | 0.230% | 2.964% | 15.931% | -70.432% | -61.329% | -70.694% | -95.846% |
| Rhythm Pharmaceuticals | 0.000% | -5.000% | -11.856% | 14.765% | -8.556% | 437.736% | 493.750% |
Comments
Corvus Pharmaceuticals (CRVS) is now covered by The Goldman Sachs Group, Inc.. They set a "buy" rating on the stock.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals (CRVS) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $33.00 price target on the stock, up from $32.00.
Show more
Ratings data for CRVS provided by MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Show more
Ratings data for CRVS provided by MarketBeat
News
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?
Immuno-oncology specialist Corvus Pharmaceuticals (NASDAQ:CRVS) reported a recent insider buy amid a year of sharp share price gains.
On June 11, 2026, David Scott Moore, acquired the direct
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
On May 15, 2026, Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals (NASDAQ:CRVS), acquiring 1,100,000 shares in the first quarter for an estimated $17.55 million based on